Victor Shi is SVP and Chief Medical Officer at Valo. Prior to joining Valo he was VP and Head of Global Clinical Development and Operations for Novartis. He is a veteran global drug developer with >20 years of experience in global drug development at Novartis across several therapeutic areas (mainly in cardio-renal and metabolic). His experience spans from the conception of a clinical program to the execution, NDA submission and approval. At Novartis, Victor led and oversaw several major global clinical development programs and completed a total of 9 NDA or sNDA submissions/approvals for multiple drugs/indications. Two landmark trials that Victor led (Entresto in patients with heart failure, and Lotrel in patients with hypertension and high CV risks) were stopped early on the strength of results of overwhelming efficacy. The results from these two trials have fundamentally changed the way how physicians worldwide treat heart failure and hypertension patients, respectively. Victor was instrumental (as co-architect) in the success of the entire Entresto development program from innovative study design to execution.

Prior to Novartis, Victor led a translational research team at Harvard University evaluating the pathogenesis of vascular remodeling after organ transplantation, CABG, and PCI. He has eight years of experience as a cardiac surgeon at a world leading hospital for cardiovascular diseases in Beijing, including a 6-month rotation at Boston Children’s Hospital. Victor received his MD at Jilin University in Changchun, China, and did his postgraduate training as a Research Fellow at the Center for Cardiovascular Disease Prevention of the Harvard School of Public Health in Boston.